Ling

Ling Su,
PhD

Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University, Venture Partner, Lilly Asia Ventures

Dr. Su is an epidemiologist and drug development professional with 25 years of industry and government experience in the US and Asia. His extensive experience spans the fields of regulatory affairs, medicinal product development strategy, clinical research, drug safety, and pharmacoepidemiology. Dr. Su is currently a Professor and Director of the Institute of Drug Regulatory Science at Shenyang Pharmaceutical University, China and a Venture Partner at Lilly Asia Ventures, based in Shanghai, China. Previously serving as the Strategic Advisor for Life Sciences at Sidley Austin and as Senior Vice President and Head of Development Greater China Region at Novartis, Dr. Su has held various research and development and management positions at Merck, Roche, and Wyeth/Pfizer. Prior to joining the private sector, he worked in the Bureau of Drugs, Ministry of Health in China and in the US FDA’s Center for Drug Evaluation and Research (CDER).